✦ LIBER ✦

Platelet-derived growth factor is decreased in patients with myeloproliferative disorders

✍ Scribed by Osamu Katoh; Akiro Kimura; Atsushi Kuramoto

Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 371 KB
Volume: 27
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.2830270409

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Decreased natural killer (NK) activity i

Decreased natural killer (NK) activity in patients with myeloproliferative disorders

✍ Paul Froom; Ester Aghai; Amalia Kinarty; Nitza Lahat 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 313 KB 👁 1 views

Circulating platelet-derived endothelial

Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients

✍ Kenji Jin-no; Masahito Tanimizu; Ichinosuke Hyodo; Yoshiyuki Nishikawa; Yasushi 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 463 KB 👁 2 views

classified into two groups based on TNM stage: early and advanced stage disease groups. PD-ECGF expressions in HCC tissues were immunohistologically examined.

Expression of platelet-derived endotheli

Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma

✍ Shinsuke Saito; Nelson Tsuno; Hirokazu Nagawa; Eiji Sunami; Jin Zhengxi; Takuya 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 323 KB 👁 2 views

## BACKGROUND. Platelet-derived endothelial cell growth factor (PD-ECGF) is an angiogenic factor that has potent chemotactic activity for endothelial cells. Although it is expressed in the majority of colorectal tumors, and some reports suggest that its high expression is related to poor prognosis,

Lack of evidence of stimulatory autoanti

Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis

✍ Jean-François Classen; Dan Henrohn; Fredrik Rorsman; Johan Lennartsson; Bernard 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 364 KB 👁 1 views

“Leukemic” pattern of in vitro growth in

“Leukemic” pattern of in vitro growth in a patient with Down syndrome and transient myeloproliferative disorder

✍ Professor Barry Mendelow; Selma Krawitz; Richard Cohn; Renée Bernstein 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 1 views

Thrombopoietin is synergistic with other

Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro

✍ Wun, Theodore; Paglieroni, Teresa; Hammond, William P.; Kaushansky, Kenneth; Fos 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 1 views

Thrombopoietin (TPO) is the primary physiologic regulator of platelet production. The effect of TPO on platelet function, both alone and in combination with other hematopoietic growth factors, adenosine diphosphate (ADP), and epinephrine, was investigated using fluorescent-labeled antibodies to the